Catalyst Funds Management’s Summit Therapeutics SMMT Stock Holding History

Catalyst Funds Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,300	Closed	-$475K	–	637
2025 Q2	$475K	Buy	+22,300	New	+$509K	0.13%	206
2024 Q3	–	Sell	-6,900	Closed	-$53.8K	–	1581
2024 Q2	$53.8K	Buy	+6,900	New	+$37.3K	0.01%	401

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Catalyst Funds Management's SMMT Position: Q3 2025 in Review

Catalyst Funds Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 22,300 shares — an estimated $475K sold.

Catalyst Funds Management first reported a position in SMMT in Q2 2024 and held it in 2 quarters. The position peaked at $475K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Catalyst Funds Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Catalyst Funds Management sold 22,300 Summit Therapeutics shares in Q3 2025, an estimated $475K.
Catalyst Funds Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 2 quarters.
Catalyst Funds Management's Summit Therapeutics position peaked at $475K in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.